DBV Technologies SA Sponsored ADR Stock

$9.81

0.62% yesterday

Nasdaq, Aug 12, 10:00 pm CET

ISIN

US23306J1016

Symbol

DBVT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

DBV Technologies SA Sponsored ADR Stock price

$9.81

-13.19 57.35% 5Y

Nasdaq, Closing price Tue, Aug 12 2025

+0.06 0.62%

ISIN

US23306J1016

Symbol

DBVT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$277.1m

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | negative

P/S

72.9 | 3.6

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

41.8%

Return on Equity

-416.7%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$3.8m | $76.5m

EBITDA

$-116.5m | $-147.9m

EBIT

$-121.7m | $-196.1m

Net Income

$-122.6m | -

Free Cash Flow

$-88.1m

Growth (TTM | estimate)

Revenue

-72.5% | 1,743.9%

EBITDA

-12.9% | -27.6%

EBIT

-31.7% | -68.4%

Net Income

-38.6% | -

Free Cash Flow

14.8%

EPS

$-1.0

FCF per Share

Short interest

0.1%

Employees

110

Rev per Employee

$40.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

DBV Technologies SA Sponsored ADR Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a DBV Technologies SA Sponsored ADR forecast:

6x Buy

75%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a DBV Technologies SA Sponsored ADR forecast:

Buy

75%

Hold

13%

Sell

13%

Analyst Estimates with Stock Price Targets

Financial data from DBV Technologies SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	3.80 3.80	72% 72% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	28 28	13% 13% 739%
- Research and Development Expense	96 96	13% 13% 2,524%
EBITDA	-117 -117	13% 13% -3,067%
- Depreciation and Amortization	5.18 5.18	148% 148% 136%
EBIT (Operating Income) EBIT	-122 -122	32% 32% -3,203%
Net Profit	-123 -123	39% 39% -3,225%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

DBV Technologies SA Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

14 days ago

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Comp...

Neutral

GlobeNewsWire

●

14 days ago

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the Second Quarter of 2025. The quarterly and half-year financial statements were approved by the Board ...

Neutral

GlobeNewsWire

●

15 days ago

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated Information Châtillon, France, July 28, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO...

More DBV Technologies SA Sponsored ADR News

Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Head office	France
CEO	Daniel Tassé
Employees	110
Founded	2002
Website	www.dbv-technologies.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now